Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CHF5188 pMDI once-daily vs budesonide and Seretide in moderate to severe persistent asthma
2009-013759-32Phase 2Completed
- Sponsor
- Chiesi Farmaceutici S.p.A.
- Start
- Oct 2009
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of budesonide + carmoterol in asthma and severe asthma (3 arms), sponsored by Chiesi Farmaceutici S.p.A. Primary endpoint: Trough FEV1 after 4 weeks of treatment. Started Oct 2009; status: completed.
02
Drugs
budesonide + carmoterol
03
Conditions
asthmasevere asthma
Beyond the preview
Go deeper on 2009-013759-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-013759-32.